FBRX · CIK 0001419041 · operating
# Forte Biosciences, Inc.
Forte Biosciences operates as a clinical-stage biopharmaceutical company focused on immunology therapeutics. The company's primary asset is FB-102, a proprietary anti-CD122 monoclonal antibody in clinical development targeting multiple autoimmune and inflammatory conditions. The therapeutic candidate is being evaluated for graft-versus-host disease, vitiligo, alopecia areata, celiac disease, and non-segmental vitiligo. As a clinical-stage entity, the company has not yet commercialized products and generates no product revenue.
The company is headquartered in Dallas, Texas and operates with a lean organizational structure of 16 full-time employees. Forte Biosciences is incorporated in Delaware and trades on the Nasdaq exchange with a market capitalization of approximately $0.4 billion. The company's operations are concentrated in the United States, with development activities centered around advancing FB-102 through clinical trials.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-12.17 | $-12.17 | -1117.0% | |
| 2023 | $-1.00 | $-1.00 | -25.0% | |
| 2022 | $-0.80 | $-0.80 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-28 | 0000950170-25-046749 | SEC ↗ |
| 2023-12-31 | 2024-03-18 | 0000950170-24-032843 | SEC ↗ |
| 2022-12-31 | 2023-03-31 | 0000950170-23-011355 | SEC ↗ |
| 2021-12-31 | 2022-03-31 | 0001564590-22-012987 | SEC ↗ |
| 2020-12-31 | 2021-03-16 | 0001564590-21-013249 | SEC ↗ |
| 2019-12-31 | 2020-02-27 | 0001564590-20-007402 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001564590-19-004933 | SEC ↗ |
| 2017-12-31 | 2018-03-09 | 0001564590-18-005132 | SEC ↗ |